Novartis Scemblix® shows superior major molecular response
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...
Source: globenewswire.com
Primary Efficacy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Primary Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Primary Efficacy Today - Breaking & Trending Today
HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...
Source: prnewswire.com
Horizon Therapeutics plc: Sustained Patient Response to KRYSTEXXA (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging
Source: finanznachrichten.de
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the... | November 5, 2022
Source: marketscreener.com
Horizon Therapeutics plc: Data Support the Use of KRYSTEXXA (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment
Source: finanznachrichten.de